DT,Connector,pairs,24,&,Series,Female,$4,Male,pin,solid,Deutsch,12,Business & Industrial , Electrical Equipment & Supplies , Wire, Cable & Conduit,/foveolarious1401652.html,federaltaxresource.us $4 12 pairs Deutsch DT Series solid pin Connector Male & Female 24 Business & Industrial Electrical Equipment & Supplies Wire, Cable & Conduit 12 pairs Deutsch DT Series solid pin & Male Female Connector 24 Sale SALE% OFF $4 12 pairs Deutsch DT Series solid pin Connector Male & Female 24 Business & Industrial Electrical Equipment & Supplies Wire, Cable & Conduit DT,Connector,pairs,24,&,Series,Female,$4,Male,pin,solid,Deutsch,12,Business & Industrial , Electrical Equipment & Supplies , Wire, Cable & Conduit,/foveolarious1401652.html,federaltaxresource.us 12 pairs Deutsch DT Series solid pin & Male Female Connector 24 Sale SALE% OFF
12 pairs Deutsch DT Series solid pin Connector Male & Female 24
$4
12 pairs Deutsch DT Series solid pin Connector Male & Female 24
|||
Item specifics
Condition:
New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is ... New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is applicable). Packaging should be the same as what is found in a retail store, unless the item was packaged by the manufacturer in non-retail packaging, such as an unprinted box or plastic bag. See the seller's listing for full details.
Compatible Wire Gauge (AWG):
14-16
Custom Bundle:
No
Number of Pins:
24
Gender:
Male & Female
Contact Material:
Nickel
MPN:
Does Not Apply
Modified Item:
No
Non-Domestic Product:
No
Model:
0460-215-16141 and 0462-209-16141
Maximum Operating Temperature (Nominal):
125°C
Protection Against Solids:
Dust Tight
Minimum Operating Temperature (Nominal):
-55°C
Maximum Operating Temperature (Actual):
125°C
Body Material:
Thermoplastic
Brand:
Deutsch
Termination Type:
Nickel
UPC:
Does not apply
12 pairs Deutsch DT Series solid pin Connector Male & Female 24
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.
Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
The Author Information section provides general guidelines and requirements for specific article types.
Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?
ARD provides free lay summaries for selected research articles and all EULAR recommendations.
These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.
The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.
Each recommendation also has an accompanying lay summary, which is also free to access.
Video Abstract
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE
To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425
Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.
Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.
